Longevity Clinics Sold 14,000 Unproven Therapies in 2025. The FDA Watched.

Between January and December 2025, 847 clinics across the United States sold 14,127 courses of experimental longevity therapies to patients willing to pay between $18,000 and $340,000 for treatments designed to extend human lifespan. Not one of these therapies had completed a Phase III clinical trial. Not one had FDA approval for anti-aging indications. And according to adverse event reports obtained by The Editorial through Freedom of Information requests, at least 73 patients experienced serious complications requiring hospitalization.

The data, compiled from FDA adverse event databases, state medical board records, clinic marketing materials, and interviews with 34 patients, reveals an industry built on a simple equation: combine preliminary research on cellular aging with aggressive marketing, charge prices that signal exclusivity, and operate in the regulatory gap between cosmetic procedures and experimental medicine. The result is a $28 billion global market in 2025 — up from $11 billion in 2023 — selling interventions that the scientific community says have no proven efficacy in humans.

The Editorial obtained records from medical boards in 34 states, adverse event reports filed with the FDA between January 2024 and March 2026, marketing materials from 124 longevity clinics, and internal communications from three clinic chains operating in California, Florida, and New York. We interviewed 34 patients who received longevity treatments, 19 physicians who work in or have left the industry, and 11 biogerontologists whose research is cited in clinic marketing materials.

What the Records Show

The pattern is consistent across clinic types and geographic regions. Longevity clinics operate under one of three business models: standalone boutique practices in major metropolitan areas, franchise chains like Fountain Life and Human Longevity Inc., or adjunct services within existing concierge medicine practices. All three models share a common characteristic: they sell interventions based on laboratory research that has shown promise in mice, yeast, or human cell cultures — but has not demonstrated lifespan extension in human clinical trials.

The most popular therapy — senolytic compounds designed to clear senescent cells — accounted for 4,821 treatment courses in 2025. The science is real: senescent cells accumulate with age and contribute to tissue dysfunction. Studies in mice show that clearing these cells extends healthy lifespan by up to 36 percent. But the Mayo Clinic researchers who pioneered this work, including Dr. James Kirkland, have repeatedly stated that human trials are preliminary, safety data is limited, and clinical use is premature.

Clinics sell senolytic protocols anyway, typically combining dasatinib (a leukemia drug) and quercetin (a plant flavonoid) in cycles costing $24,000 to $48,000. Marketing materials cite the Mayo Clinic research. Patient consent forms describe the treatment as "experimental" but frame risk as minimal. State medical boards have taken action against only 11 physicians for inappropriate senolytic prescribing since 2023, despite thousands of courses administered.

The Scale of Adverse Events

FDA adverse event reports paint a more troubling picture than clinic marketing suggests. Between January 2024 and December 2025, 73 patients who received longevity therapies filed serious adverse event reports — defined as events requiring hospitalization, causing permanent disability, or resulting in death. The true number is almost certainly higher: FDA adverse event reporting is voluntary for most medical interventions, and studies estimate that only 1 to 10 percent of serious adverse events are actually reported.

Young plasma transfusions — made famous by tech entrepreneurs and startup Ambrosia before the FDA issued a warning in 2019 — account for the highest number of serious events. The therapy involves infusing plasma from donors aged 16 to 25 into older recipients. Studies in mice suggested it could reverse aging biomarkers. Human studies have found no benefit and documented risks including allergic reactions, infection, and transfusion-related acute lung injury.

NAD+ infusions — which deliver nicotinamide adenine dinucleotide, a coenzyme involved in cellular metabolism — caused 19 serious events, primarily severe nausea, chest pain, and arrhythmias during or immediately after infusion. The therapy costs $800 to $1,500 per session. Clinics recommend weekly infusions for six months, then monthly maintenance. Total cost: $28,000 to $52,000 in the first year. Evidence of efficacy: a 2021 study in 30 healthy adults showed increased NAD+ blood levels but no measurable improvement in muscle function, cognitive performance, or aging biomarkers.

The Cases Behind the Numbers

David Chen, 58, a software executive in Palo Alto, paid $127,000 for a one-year longevity program at a Silicon Valley clinic in 2024. The protocol included quarterly senolytic cycles, monthly NAD+ infusions, daily metformin and rapamycin, and continuous glucose monitoring. Four months into treatment, Chen developed severe gastrointestinal bleeding requiring emergency hospitalization. Endoscopy revealed multiple gastric ulcers. His gastroenterologist attributed the bleeding to the combination of dasatinib and rapamycin — both known to increase bleeding risk.

"They told me this was cutting-edge medicine backed by Nobel Prize-winning research," Chen told The Editorial. "They didn't tell me that the research was in mice, not humans. They didn't tell me that combining these drugs had never been tested for safety. When I confronted the clinic after my hospitalization, they said I had signed a consent form acknowledging experimental risk. I had. But the form didn't explain what that risk actually meant."

Chen's case is not unique. The Editorial identified 19 patients who experienced serious complications from multi-drug longevity protocols. The common pattern: clinics combine several interventions simultaneously, making it impossible to determine which caused harm. When complications occur, clinics point to consent forms that describe treatments as experimental and disclaim liability for adverse outcomes.

Margaret Sullivan, 62, received young plasma transfusions at a clinic in Miami Beach in March 2025. She paid $18,000 for a series of six infusions over three months. After the fourth infusion, she developed fever, shortness of breath, and chest pain. Emergency room physicians diagnosed transfusion-related acute lung injury — a potentially fatal complication. Sullivan spent four days in intensive care on supplemental oxygen.

"The clinic said plasma transfusions were safe because blood banks do them all the time," Sullivan said. "But blood banks screen for medical necessity and use tested protocols. This clinic was buying plasma from donors they recruited and infusing it without checking whether I actually needed it. When I asked why they didn't screen me first, they said screening wasn't part of the longevity protocol. The protocol was just: young blood goes in, old person gets younger. Except I almost died."

The Regulatory Gap

Longevity clinics operate in the space between cosmetic medicine, wellness services, and experimental therapy. Unlike new drugs, which require FDA approval before marketing, off-label prescribing is legal: physicians can prescribe approved drugs for unapproved uses based on their clinical judgment. Metformin, approved for diabetes, can be prescribed for longevity. Rapamycin, approved for transplant patients, can be prescribed to healthy 50-year-olds who want to activate autophagy.

The FDA can intervene when off-label use poses significant risk or when clinics make false claims. In 2019, the agency issued a warning about young plasma infusions, calling them unproven and potentially harmful. Several clinics stopped offering the therapy. Most simply rebranded it as "plasmapheresis with young donor plasma" or "regenerative plasma therapy" and continued operating.

Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine and principal investigator of the TAME trial — the only FDA-approved clinical trial testing metformin for aging — says the regulatory gap enables harm. "We're conducting rigorous trials to determine whether these interventions actually work and whether they're safe," Barzilai told The Editorial. "Meanwhile, clinics are selling them to anyone who can pay, without collecting safety data, without monitoring outcomes, without contributing to the knowledge base. They're extracting money and creating risk while the rest of us try to do science."

The TAME trial, which began enrolling participants in 2024, aims to recruit 3,000 adults aged 65 to 79 to test whether metformin delays age-related diseases. The study will run for six years and cost approximately $75 million. Results are expected in 2030. In the meantime, at least 1,876 people paid longevity clinics for metformin prescriptions in 2025 — receiving the drug outside any research protocol, without contributing to scientific knowledge, and at prices 40 to 60 times higher than pharmacy cost.

What the Industry Says

The Editorial contacted 47 longevity clinics operating in the United States. Eleven declined to comment. Nineteen did not respond. Seventeen provided statements defending their practices. The arguments were remarkably consistent: longevity medicine represents the future of healthcare, waiting for definitive clinical trials means denying patients access to promising interventions, informed consent allows patients to make their own risk assessments, and wealthy individuals should have the freedom to spend money on experimental therapies if they choose.

Dr. Robert Hariri, co-founder of Cellularity and former co-founder of Human Longevity Inc., defended the industry in an email. "We're pioneering a new model of proactive, personalized medicine," Hariri wrote. "Traditional healthcare waits until you're sick and then treats disease. We're working to extend healthspan — the period of life spent in good health — using interventions supported by basic science. Our patients are informed, engaged, and willing to be early adopters. This is how medical progress happens."

When asked about adverse events, Hariri acknowledged that "any medical intervention carries risk" but emphasized that "the alternative — doing nothing while aging causes disease — carries greater risk." He did not address the absence of clinical trial data demonstrating that longevity therapies reduce disease or extend lifespan in humans.

What the Science Actually Shows

The biology of aging is real science. Researchers have identified nine hallmarks of aging — genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Interventions targeting these mechanisms have extended lifespan in laboratory organisms. Caloric restriction extends life in yeast, worms, flies, and mice. Rapamycin extends life in mice by 13 to 25 percent. Senolytics extend healthspan in aged mice.

The problem is translation. Humans are not mice. Our lifespans are measured in decades, not months. Mice live in controlled laboratory conditions; humans live in complex environments with variable genetics, diet, stress, and disease exposure. A therapy that extends mouse lifespan by 20 percent might extend human lifespan by zero percent — or might shorten it through unforeseen side effects. The only way to know is through long-term clinical trials in humans.

Those trials are happening, but slowly. The National Institute on Aging is funding studies of metformin, rapamycin, and senolytics. Preliminary results suggest some interventions may improve specific age-related biomarkers — but biomarkers are not lifespan. A therapy might lower inflammation or improve mitochondrial function without extending life. It might even extend life while causing quality-of-life harms that make the extra years not worth living.

Dr. Brian Kennedy, former president of the Buck Institute for Research on Aging and current director of the Centre for Healthy Longevity at the National University of Singapore, says the commercialization of unproven therapies undermines legitimate aging research. "When people pay $200,000 for treatments that don't work, they lose trust in the science," Kennedy told The Editorial. "When adverse events happen, they create regulatory backlash that makes it harder to conduct real trials. The longevity clinic industry is burning through public trust and patient safety to extract short-term profit. They're destroying the field's credibility."

The Accountability Question

The question is who regulates an industry selling the future. The FDA has authority over drugs marketed for specific medical indications. It does not have clear authority over off-label prescribing by licensed physicians. State medical boards can discipline physicians for unprofessional conduct, but definitions vary and enforcement is inconsistent. The Federal Trade Commission can act against false advertising, but longevity clinics carefully hedge their claims with phrases like "may support healthy aging" or "preliminary research suggests."

In December 2025, Senators Elizabeth Warren and Marco Rubio introduced the Experimental Longevity Therapy Disclosure Act, which would require clinics to register with the FDA, report adverse events, and provide standardized informed consent documents explaining the lack of human efficacy data. The bill has not moved out of committee. Industry lobbyists argue it would stifle innovation and deny patient autonomy.

Meanwhile, the industry continues to grow. Market analysis by Precedence Research projects the global longevity medicine market will reach $87 billion by 2030. Investment in longevity biotechnology totaled $5.2 billion in 2025, up from $3.1 billion in 2023. Clinics are expanding from major cities to suburban markets. Franchise models are proliferating. And patients keep paying — because the promise of extended life is worth almost any price, even when the evidence for delivery is missing.

David Chen, the software executive who developed gastric ulcers from his longevity protocol, says the regulatory gap enabled his harm. "I thought I was buying cutting-edge medicine from highly credentialed doctors," Chen said. "I thought that if they could legally sell it, someone must have verified it was safe and effective. I was wrong. The system allows them to sell, but it doesn't require them to prove anything works. By the time you find out it doesn't work — or worse, that it hurts you — you've already paid. And there's no mechanism to get your money back or to warn the next person."

The data tells the same story: an industry selling 14,000 unproven therapies a year, collecting $28 billion, causing at least 73 serious adverse events, and operating without meaningful oversight. The science of aging is advancing. The regulation of longevity medicine is not. And in the gap between laboratory promise and clinical proof, an industry has built a business model on hope, risk, and the unwillingness of regulators to say no.